The 2024 EASL guidelines on MASLD are already out of date on treatment, and that's a good problem to have. In part 2, Pradeep Mundre and Professor Sven Francque (Antwerp), guideline co-author, walk through what works now. Lifestyle still earns the hardest numbers: 7% body weight loss for resolution of steatohepatitis, 10% for fibrosis regression. Resmetirom, a liver-targeted thyroid hormone receptor beta agonist, is now approved for F2-F3 fibrosis (though not in every EU country). Semaglutide has produced positive phase 3 data in MASH and an updated guideline is on the way. Sven also covers where pioglitazone, obeticholic acid, and bariatric surgery sit, the particularities of liver transplantation in this older, comorbid population, and an honest answer to what a hepatology trainee should expect from this field. Catch part 1 first if you missed it.

MASLD guidelines